AP NEWS

Stem Cell Therapies in CVMD 2018-2025 - New Stem Cell Therapy Approvals will Drive CVMD Market Growth - ResearchAndMarkets.com

August 23, 2018

DUBLIN--(BUSINESS WIRE)--Aug 23, 2018--The “Stem Cell Therapies in CVMD” report has been added to ResearchAndMarkets.com’s offering.

This report provides an assessment of the pipeline, clinical, and commercial landscape of stem cell therapies in CVMD. Overall, it is expected that new stem cell therapy approvals will drive CVMD market growth from 2018-2025.

The FDA has put out a comprehensive policy framework for the development and oversight of regenerative medicine products through the 21st Century Cures Act, legislation for an expedited approval path for cellular medicines designated as regenerative medicine advanced therapies (RMATs) to patients who need them faster and more efficiently.

Studies of stem cell therapies targeting cardiovascular indications such as heart failure (HF), myocardial infarction (MI), cardiomyopathy (CM), and left ventricular dysfunction (LVD) aim to demonstrate that stem cells injected into the circulation or directly into the injured heart tissue improve cardiac function and/or induce the formation of new capillaries.

The majority of CVMD pipeline candidates are in preclinical development, with ~73% of CVMD stem cell pipeline therapies specifically targeting cardiovascular indications. Representative stem cell types that are being investigated in clinical trials towards CV indications include mesenchymal precursor, ischemia-tolerant mesenchymal, myoblast, immunomodulatory progenitor, and heart-derived stem cells.

Currently, there is an absence of big pharma investment in cardiovascular stem cell therapy clinical development, with the majority of the R&D efforts in this space being undertaken by small biotech companies.

Scope

Overview of CVMD and Stem Cells: epidemiology and regulatory oversight Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors Market Access: considerations for reimbursement, pricing, and unmet needs Market Outlook: competitive assessment and key market events (2018-2025)

Companies Featured

Mesoblast U.S. Stemcell Celixir Capricor Stemedica Healios Athersys SanBio

Key Topics Covered

1. Introduction

2. Executive Summary

3. Overview - Stem Cells, CVMD, Epidemiology

4. Regulatory Oversight of Stem Cell Therapies

5. Pipeline Assessment, Profiled Stem Cell Therapies

6. Clinical Trials and Key Developers

7. Market Access: Reimbursement, Pricing, Unmet Need

8. Market Outlook

For more information about this report visit https://www.researchandmarkets.com/research/36wnhr/stem_cell?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180823005672/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Stem Cells

KEYWORD:

INDUSTRY KEYWORD: STEM CELLS HEALTH CARDIOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/23/2018 02:24 PM/DISC: 08/23/2018 02:24 PM

http://www.businesswire.com/news/home/20180823005672/en

AP RADIO
Update hourly